Availablity in Hospital Keningau:
- Verorab (PVRV - purified inactivated rabies vaccine, prepared on vero cell) – Sanofi Pasteur
Risk Category:
RISK CATEGORY | TYPE OF EXPOSURE | ACTION TO BE TAKEN |
1 | Touching/feeding animal. Licking of intact skin. | Nil if history is reliable. If history not reliable, treat as category 2. |
2 | Nibbling of uncovered skin. Superficial scratch, no bleeding. Licking of broken skin. | Apply wound treatment. Administer vaccine. Do not administer anti-rabies immunoglobulin. Stop vaccination if animal is rabies negative in laboratory tests, or remains healthy after 10 -14 days observation (dog or cat). Continue vaccination if animal is not found/captured. |
3 | Bites/scratches which penetrate the skin and draw blood. Licking mucous membrane. Multiple bites. Any wild animals bites | Apply wound treatment. Administer vaccine. Administer anti-rabies immunoglobulin. Administer anti-tetanus and antibiotic treatment. Stop vaccination if animal is rabies negative in laboratory tests, or remains healthy after 10 - 14 days observation (dog or cat). Continue vaccination if animal is not found/captured. |
- Effective treatment soon (within a few days, but as soon as possible) after exposure to rabies can prevent the onset of symptoms and death.
- Post-exposure prevention consists of local treatment of the wound, administration of rabies immunoglobulin (if indicated), and immediate vaccination
Post Exposure Vaccine (PEP)
- Indicated for Risk Category 2 and 3
- Vaccination after exposure (post-exposure) is recommended for all individuals who have had contact with an animal (e.g., bites or abrasions) that they believe may be, or which is proven to be, rabid.
- Area for injection for vaccine;
- i. Adult - IM at deltoid area
- ii. Children – IM at anterolateral aspect of thigh.
- Pregnancy and Infancy are never contraindications to PEP.
Status | Dosing |
Previously unvaccinated people |
|
Previously vaccinated people |
|
Immunocompromised patient (corticosteroids, other immunosuppressive agents, chloroquine, and immunosuppressive illnesses e.g. congenital immunodeficiency, HIV, leukaemia, lymphoma, generalized malignancy) |
|
Rabies Immunoglobulin:
- Rabies Immunoglobulin is indicated for Risk Category 3 only
- Human anti-rabies immunoglobulin(HRIG)-20iu/kg body weight
- Heterologous (equine) immunoglobulin(RIG) -40iu/kg body weight
- Route of administration: IM at an anatomical site distant from vaccine administration.
- If immunoglobulin is not available, it can be delayed up to 7 days post 1st vaccine given.
- Beyond the seventh day, RIG is not recommended since an antibody response to the vaccine is presumed to have occurred.
References:
- Interim Guideline for Human Rabies Prevention and Control in Malaysia.
- http://www.who.int/rabies/human/postexp/en/
- WHO Guide for Rabies Pre and Post Exposure Prophylaxis In Humans
Post a Comment